Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo

Pharmaceutical Research

Volumn 13, Issue 11, 1996, Pages 1668-1672

  Lueßen, Henrik L ^a,b   De Leeuw, Bas J ^a   Langemeÿer, Mariska W E ^a   De Boer, A G ^a   Verhoef, J Coos ^a   Junginger, Hans E ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LTS Lohmann Therapie Systeme AG   (Germany)

Author keywords

Buserelin; Carbomer; Chitosan; Intestinal absorption in vivo; Intraduodenal application; Peroral peptide drug delivery; Poly(acrylates)

Indexed keywords

ADHESIVE AGENT; BUSERELIN ACETATE; CARBOMER; CHITOSAN;

ANIMAL EXPERIMENT; ARTICLE; BIOAVAILABILITY; DRUG ABSORPTION; INTESTINE ABSORPTION; INTRADUODENAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ACRYLIC RESINS; ADHESIVES; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BUSERELIN; CHITIN; CHITOSAN; DRUG CARRIERS; DRUG INTERACTIONS; FREEZE DRYING; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; MALE; RATS; RATS, WISTAR;

EID: 0030453145     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016488623022     Document Type: Article

References (24)

1. R. T. Borchardt. Capsugel Liberary, 11-19 (1991).
2. H. Vilhardt and S. Lundin. Gen. Pharmac. 17:481-483 (1986).
3. C. Larsen, M. Niebuhr Jørgensen, B. Tommerup, N. Mygind, E. E. Dagrosa, H. G. Grigoleit, and V. Malerczyk. Eur. J. Clin. Pharmacol. 33:155-159 (1987).
4. A. S. Harris. J. Drug Targeting 1:101-116 (1993).
5. I. Matthes, F. Nimmerfall, and H. Sucker. Pharmazie 47:609-613 (1992).
6. X. H. Zhou. J. Controlled Rel. 29:239-252 (1994).
7. H. L. Lueßen, B. J. de Leeuw, D. Pérard, C.-M. Lehr, A. G. de Boer, J. C. Verhoef, and H. E. Junginger. Eur. J. Pharm. Sci. 4:117-128 (1996).
8. H. L. Lueßen, G. Borchard, J. C. Verhoef, C.-M. Lehr, A. G. de Boer, and H. E. Junginger. Pharm. Res. 12:1293-1298 (1995).
9. G. Borchard, H. L. Lueßen, A. G. de Boer, J. C. Verhoef, C.-M. Lehr, and H. E. Junginger. J. Controlled Rel. 39:131-138 (1996).
10. H. L. Lueßen, C.-O. Rentel, A. F. Kotzé, C.-M. Lehr, A. G. de Boer, J. C. Verhoef, and H. E. Junginger. J. Controlled Rel., (in press) (1996).
11. L. Illum, N. F. Farraj, and S. S. Davis. Pharm. Res. 11:1186-1189 (1994).
12. J.-M. Gu, J. R. Robinson, and A.-H. S. Leung. Crit. Rev. Therap. Drug Carrier Sys. 5:21-67 (1988).
13. C.-M. Lehr, J. A. Bouwstra, E. H. Schacht, and H. E. Junginger. Int. J. Pharm. 78:43-48 (1992).
14. Y. Akiyama, H. L. Lueßen, A. G. de Boer, J. C. Verhoef, and H. E. Junginger. Int. J. Pharm., 136:155-163 (1996).
15. H. M. Behre, J. Sandow, and E. Nieschlag. Arzneim.-Forsch./ Drug Res. 42:80-84 (1992).
16. J. B. M. M. van Bree, A. G. de Boer, M. Danhof, J. Verhoef, T. B. van Wimersma Greidanus, and D. D. Breimer. Peptides 9:555-559 (1988).
17. M. Gibaldi and D. Perrier. In: J. Swarbrick (ed.), Drugs and the pharmaceutical sciences, Vol. 1, Marcel Dekker, New York, 1975, pp. 409-424.
18. J. Sandow. In A. E. Schindler and K. W. Schweppe (eds.), Endometriose - Neue Therapiemöglichkeiten durch Buserelin. Walter de Gryter, Berlin-New York, 1989, 23-42.
19. M. J. Brownstein. In G. J. Siegel (ed.), Basic neurochemistry: molecular, cellular, and medical aspects. Raven Press, New York, 1989, 287-309.
20. F. J. Holland, L. Fishman, D. C. Costigan, L. Luna, and S. Leeder. J. Clin. Endocrinol. Metab. 63:1065-1070 (1986).
21. A. J. Hoogstraate, J. C. Verhoef, A. Pijpers, L. A. M. G. van Leengoed, J. H. M. Verheijden, H. E. Junginger, and H. E. Boddé. Pharm. Res. 13:1233-1237 (1996).
22. Suprecur® - Hoechst Fachinformation.
23. Y. Akiyama, H. L. Lueßen, A. G. de Boer, J. C. Verhoef, and H. E. Junginger. Int. J. Pharm., 138:13-23 (1996).
24. B. J. de Leeuw, H. L. Lueßen, A. F. Kotzé, A. G. de Boer, J. C. Verhoef, and H. E. Junginger. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 23:845-846 (1996).